Synopsis Glaucoma is a progressive optic neuropathy characterized by damage to the optic nerve head, degeneration of retinal ganglion cells, and progressive visual field loss. Current treatment strategies aim at reducing the intraocular pressure (IOP) by topical drugs, laser therapy, and surgery, to prevent the disease progression. However, there have been reports of ocular and periocular adverse events with their use.
Omidenepag isopropyl (OMDI) is a topical ocular hypotensive drug, which is non-inferior to latanoprost and is safe and tolerable in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). This Journal Watch discusses the study “ Omidenepag Isopropyl versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study ” from the American Journal of Ophthalmology . Authors : Makoto Aihara, Fenghe Lu, Hisashi Kawata, et…
